Agensys, Inc. and Seattle Genetics, Inc. (SGEN) Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer
6/4/2012 10:40:53 AM
More...
|
Astellas Pharma Inc. (YPH.BE) Adds Two Key Senior Executives at Agensys, Inc.
12/1/2011 3:02:21 PM
More...
|
Seattle Genetics, Inc. (SGEN) and Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE), Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration
6/9/2011 9:27:27 AM
More...
|
Agensys, Inc. Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President
11/2/2010 7:14:41 AM
More...
|
Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE), and Seattle Genetics, Inc. (SGEN) Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer
10/20/2010 10:27:54 AM
More...
|
Seattle Genetics, Inc. (SGEN) Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE)
9/2/2010 10:44:59 AM
More...
|
Seattle Genetics, Inc. (SGEN) Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE); Seattle Has Received $130 Million to date With Potential to Receive $2.7 Billion
9/2/2010 7:43:55 AM
More...
|
Agensys, Inc. Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
9/1/2010 8:18:50 AM
More...
|
Seattle Genetics, Inc. (SGEN) and Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE), Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer
7/20/2010 8:07:24 AM
More...
|
Seattle Genetics, Inc. (SGEN) andAgensys, Inc., an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR
4/21/2010 12:00:23 PM
More...
|
|